Although most weight loss drugs fall into the GLP-1 agonist category, ongoing research may reveal new roles for GLP-1 antagonists in treating obesity
These reports have not materialized in online discussions
Chung PH, Scott JF and Morey AF
Until those data mature, clinicians should frame Wegovys MASH indication as evidencesupported for histologic response but still under confirmatory evaluation for hard liver outcomes. Safety profile and risk management Safety considerations for Wegovy are dominated by its GLP1 class effects and includes both common, generally manageable GI symptoms and less frequent but clinically significant risks
82 In models of neurodegeneration such as APP/PS1 mice, liraglutide treatment normalizes synaptic markersincluding PSD95 and synaptophysinand increases dendritic spine density, correlating with improved cognitive performance
It is conceivable that metformin may be able to potentiate or strengthen the vascular protective effects of GLP-1 and its analogues